Figure 4.

Treatment with TCR+iIL-12 T cells results in lowered numbers of CD8 and TCR transgene-positive T cells in blood. HLA-A2 transgenic mice bearing established B16:A2-YLEP tumors were conditioned and treated with T cells as described in legend to Figure 3. (A) Peripheral blood was collected from mice at the indicated time points after T cell transfer and absolute numbers of gp100/HLA-A2 pMHC-binding CD8 T cells were determined by flow cytometry. Data are presented as mean numbers per μl blood±SEM (n = 4–6). (B) depicts the mean ratio of CD8/CD4 positive therapeutic T cells at day 6 after T cell transfer ±SEM (n = 4–6). Statistically significant differences between treatment groups were calculated with Student's t-test: *p < 0.05; ** p< 0.01.